SEC Filing Document

Company: DUKE Robotics Corp.
Ticker: DUKR
CIK: 1638911
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2026-04-27
Accession Number: 0001213900-26-048102
Exchange: OTC
SIC Code: 3721
SIC Description: Aircraft
URL: https://www.sec.gov/Archives/edgar/data/1638911/000121390026048102/ea028763601ex1-1.htm

Chunk 14 of 21
Word Count: 1290
Character Count: 7994

Document Content:

affiliates or any selected dealer shall be deemed to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other transactions contemplated by this Agreement. Notwithstanding anything in this Agreement to the contrary, the Company acknowledges that the Underwriters may have financial interests in the success of the Offering that are not limited to the difference between the price to the public and the purchase price paid to the Company by the Underwriters for the shares and the Underwriters have no obligation to disclose, or account to the Company for, any of such additional financial interests. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any breach or alleged breach of fiduciary duty by the Underwriters.

4.14 Warrant
Shares. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the issuance
of the Warrant Shares or if the Warrant is exercised via cashless exercise at a time when such Warrant Shares would be eligible for resale
under Rule 144 by a non-affiliate of the Company, the Warrant Shares issued pursuant to any such exercise shall be issued free of all
restrictive legends. If at any time following the date hereof the Registration Statement (or any subsequent registration statement registering
the sale or resale of the Warrant Shares) is not effective or is not otherwise available for the sale of the Warrant Shares, the Company
shall immediately notify the holders of the Warrants in writing that such registration statement is not then effective and thereafter
shall promptly notify such holders when the registration statement is effective again and available for the sale of the Warrant Shares
(it being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or any holder thereof to sell,
any of the Warrant Shares in compliance with applicable federal and state securities laws).

4.15 Board
Composition and Board Designations. The Company shall ensure that: (i) the qualifications of the persons serving as board members
and the overall composition of the Board of Directors comply with the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder
and with the listing requirements of the Trading Market and (ii) if applicable, at least one member of the Board of Directors qualifies
as a “financial expert” as such term is defined under the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder.

4.16 Securities
Laws Disclosure; Publicity. At the request of the Representative, by 9:00 a.m. (New York City time) on the date hereof, or, if this
Agreement is executed after 9:00 a.m. (New York City time) by the time reasonably requested by the Representative, the Company shall issue
a press release disclosing the material terms of the Offering. The Company and the Representative shall consult with each other in issuing
any press releases with respect to the Offering, and neither the Company nor any Underwriter shall issue any such press release nor otherwise
make any such public statement without the prior consent of the Company, with respect to any other press release of such Underwriter,
or without the prior consent of such Underwriter, with respect to any press release of the Company, which consent shall not unreasonably
be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other
party with prior notice of such public statement or communication. The Company will not issue press releases or engage in any other publicity,
without the Representative’s prior written consent, which consent shall not be unreasonably withheld, for a period ending at 5:00
p.m. (New York City time) on the first Business Day following the 45th day following the Closing Date, other than normal and customary
releases issued in the ordinary course of the Company’s business.

4.17 Shareholder
Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Underwriter
of the Securities is an “Acquiring Person” under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that any Underwriter of Securities could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities except if and to the extent required by applicable law.

4.18 Reservation
of Common Stock. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all
times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Option
Shares pursuant to the Over-Allotment Option, Warrant Shares pursuant to any exercise of the Warrants and shares of Common Stock is suable
upon exercise of the Representative’s Warrants.

4.19 Listing
of Common Stock. The Common Stock has been approved for trading on the Trading Market. The Company agrees to use its best efforts
to effect and maintain the trading of the Common Stock on the Trading Market for at least three (3) years after the Closing Date.

4.20 Right
of First Refusal. Effective upon the Closing and for a period of eighteen (18) months from the Closing Date, the Company hereby grants
the Representative a right of first refusal to act as sole managing underwriter and sole book runner, sole placement agent, or sole sales
agent for any and all of the Company’s future public or private equity, equity-linked, convertible or debt offerings (excluding
commercial bank debt) (collectively, a “Subject Transaction”) in the Unites States for which the Company retains the
services of an underwriter, agent, advisor, finder or other person or entity in connection with such offering during such eighteen (18)
month period of the Company, or any successor to or any subsidiary of the Company. The Representative shall have the sole right to determine
whether or not any other broker dealer shall have the right to participate in the Subject Transactions and the economic terms of such
participation. For the avoidance of any doubt, the Company shall not retain, engage or solicit any additional investment bank, book-runner,
financial advisor, underwriter and/or placement agent in a Subject Transaction without the express written consent of the Representative.
The right granted to the Representative pursuant to this Section 4.20 shall not apply to securities sold by the Company directly to its
directors and affiliates, so long as no broker-dealer is involved in such a transaction. The Company shall provide written notice of its
offer to engage the Representative with respect to a Subject Transaction and the Representative shall notify the Company within ten (10)
Business Days of its receipt of such written offer as to whether or not it agrees to accept such retention. If the Representative declines
such retention (or does not respond within the ten (10) Business Day notice period), then the Company shall have no further obligations
to the Representative pursuant to this Section 4.20 with respect to such Subject Transaction. For the avoidance of doubt, during the eighteen
(18) month period covered by this Section 4.20, the Company shall provide written notice to the Representative prior to each Subject Transaction.

4.21 Subsequent
Equity Sales.

(a) Except
for Exempt Issuances, from the date hereof until six (6) months after the Closing Date, neither the Company nor any Subsidiary shall issue,
enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents.